Author: Editor

Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center elaborates on the preferred agents on the 2nd line setting of renal cell carcinoma if a patient progresses on pembrolizumab/axitinib or ipilimumab/nivolumab.

Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center shares on how to decide between combinations of immuno-oncology (I-O) and TKIs for treating 1st line renal cell carcinoma (RCC).

Immunotherapies are amazing drugs against cancer. However, they still fail for too many patients. This video series presents IMPRES and TIDE, two of the best predictors of cancer immunotherapy outcomes. It also shows an easy way to combine them and improve their predictions. Finally, it makes suggestions of practical ways to contribute to research on this topic. You can support this work by making a donation: https://donorbox.org/better-predict-cancer-immunotherapy-results You can also ask for collaboration: https://mostaphabenhenda.typeform.com/to/fPEidr Text transcription: https://medium.com/the-ai-lab/how-to-better-predict-cancer-immunotherapy-results-f81747af75c8

Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center shares the TITAN Study outcomes, investigating apalutamide in metastatic castration-sensitive prostate cancer (mCSPC).

Nancy A Dawson MD, Professor of Medicine at Lombardi Cancer Center discusses her view on the ENZAMET Study while comparing testosterone suppression versus testosterone suppression + enzalutamide in metastatic hormone-sensitive prostate cancer presented at ASCO 2019.

Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope discusses details from APACT study, a phase III trial of adjuvant nab-paclitaxel plus gemcitabine.

Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope shares statistics and data on strategies that are emerging concerning BRCA mutations and pancreatic cancer.

Vincent Chung MD, Associate Clinical Professor and Medical Oncologist at City of Hope provides outcomes on the POLO Trial with olaparib in metastatic pancreatic cancer.

Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency discusses upcoming prostate cancer PARP inhibitor trials and what the field will be evolving into soon.

Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency elaborates on the importance of biomarker selection trials. Biomarker trials may help guide prostate cancer patients respond to therapies.

Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency discusses the design differences between ENZAMET and TITAN studies presented at ASCO 2019.

Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency explains what came out of the metastatic castration-sensitive prostate cancer (mCSPC) TITAN study.

Paul M. Barr MD, Associate Professor of Medicine at Wilmot Cancer Institute elaborates on the role of CAR-T cell therapy while in the treatment of B-cell lymphomas.

Paul M.Barr MD Associate Professor of Medicine at Wilmot Cancer Institute explains the results found of the RESONATE Trial that was evaluating ibrutinib versus ofatumumab in relapsed chronic lymphocytic leukemia (CLL).

Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute discusses the data found in the recent CLL-14 study in chronic lymphocytic leukemia (CLL).

Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute provides his opinion on ibrutinib in 1st line chronic lymphocytic leukemia (CLL).

Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology follows up on the long-term Checkmate-004 in metastatic melanoma and provides outcomes from the study.

Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology elaborates on the IMDC classification role in the treatment of decision-making.

Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology provides some recent trial investigations using immuno-oncology and TKIs in renal cell carcinoma.

Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses the preferred agents in the 2nd line setting of RCC once a patient has progressed on pembrolizumab/axitinib or ipilimumab/nivolumab.

Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses how to select between different combinations of immuno-oncology and TKIs that are available and for the treatment of 1st line renal cell carcinoma (RCC).

Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School explains the next steps a patient with hepatocellular carcinoma (HCC) can do if they fail the 1st line therapy with immunocology.

Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School tells us his thoughts on KEYNOTE-62. This is investigating pembrolizumab in HER2, PD-L1 positive advanced gastroesophageal cancer.

Thomas A. Abrams, Senior Physician and Assistant Medical Professor at Harvard Medical School provides results about the APACT Study. APACT Study is a phase III trial of adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine for surgically resected pancreatic adenocarcinoma.

Dr. Thomas A. Abrams, Senior Physician and Assistant Professor of Medicine at Harvard Medical School discusses whether the POLO Trial with olaparib in metastatic pancreatic cancer is practice changing with respect to patients.

Lung Cancer Video Library Mandarin – Consolidation Radiation After a Good Response to 1st Line.mp4

Lung Cancer Video Library Mandarin – Combinations of Immunotherapy Agents in Advanced NSCLC.mp4

Lung Cancer Video Library Mandarin -The Basics of Managing Immune Mediated Side Effects.mp4

Lung Cancer Video Library Mandarin – Tumor Mutation Burden Current Status.mp4

Lung Cancer Video Library Mandarin – Rapid Progression Through First Line Treatment What Next.mp4

Lung Cancer Video Library Mandarin – Immunotherapy in Stage III NSCLC PACIFIC Trial and Imfinzi.mp4         mandarin, immunotherapy in stage iii nsclc, pacific trial, imfinzi, lung cancer 

Lung Cancer Video Library Mandarin – Immunotherapy Combos in Adv Squamous Non Small Cell Lung Cancer.mp4

Lung Cancer Video Library Mandarin – Immunotherapy Combos in Adv Non Squamous NSCLC.mp4

Lung Cancer Video Library Mandarin – Evolving Standards for Molecular Testing in Advanced NSCLC.mp4

Lung Cancer Video Library Mandarin – Does Immunotherapy Work with Driver Mutations like EGFR ALK.mp4

Harold A. Burstein, M.D, discusses guideline updates on integration results from TAILORx. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline UpdateIntegration of Results from TAILORx Guideline Question For women with early-stage invasive breast cancer, which other biomarkers have demonstrated clinical utility to guide decisions on the need for adjuvant systemic therapy? Target Population Women with early-stage invasive breast cancer being considered for adjuvant systemic therapy. Target Audience Medical, surgical, and radiation oncologists; oncology nurses and physician assistants; pathologists; general practitioners; and patients. Methods An Expert Panel was…

Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses Updates On The FORTE Trial: 3 Arm Study, Higher Amount Of Persistent MRD At One Year In Patients Who Received A Transplant.

Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses Smoldering Myeloma ECOG Trial: Patients With Intermediate & High Risk MM Had An Improved Time To Progression Compared To Those Being Observed.

Philip McCarthy MD @plmcarthymd Of Roswell Park Comprehensive Cancer Center Discusses IMWG Classification Of Smoldering Myeloma: Incorporates Earlier Features Of Disease, When You Have At Least 1 Cytogenetic Abnormality It Increases Progression.

Thomas Yau MD, MBBS Of University of Hong Kong Discusses Nivolumab + Ipilimumab Combo Therapy In Patients with aHCC Results From CheckMate 040: ORR of 14& mOS of 16 Months, First Report of Efficacy & Safety of The NIVO + IPI combo in SOR-Treated patients With aHCC. BACKROUND: NIVO monotherapy (mono) is approved for sorafenib (SOR)-treated pts with HCC based on data from CheckMate 040 (NCT01658878), which reported an objective response rate (ORR) of 14% and median overall survival (mOS) of 16 months (mo). This is the first report of efficacy and safety of the NIVO + IPI combination in…

Larissa Nekhlyudov MD MPH Of Brigham & Womens Hospital/Dana-Farber Cancer Institute, Harvard Medical School Discusses Bringing Primary Physician Back Into The Care Of Patients With Cancer: Not All Primary Care Physicians Feel Comfortable Or Would Like To Engage With Their Patients While They Are Getting Cancer Care. BACKROUND: CancerLinQ Discovery (CLQD) is a real-world dataset (RWD) derived from electronic health records across the US. This analysis builds on the prior observation of cautioned use of bevacizumab (Bev) among older adults using Medicare claims data. The goals of this study are to estimate the prevalence and incidence of hypertension (HT) and…

Larissa Nekhlyudov MD MPH Of Brigham & Womens Hospital/Dana-Farber Cancer Institute, Harvard Medical School Discusses Need To Optimize Communication & Care Coordination: Sexual Health Is Important & Doctors Need To Ask Questions About It, Electronic Health Records Have Potential To Improve Communication. BACKROUND: CancerLinQ Discovery (CLQD) is a real-world dataset (RWD) derived from electronic health records across the US. This analysis builds on the prior observation of cautioned use of bevacizumab (Bev) among older adults using Medicare claims data. The goals of this study are to estimate the prevalence and incidence of hypertension (HT) and blood pressure (BP) patterns among…

Aref Al-Kali MD Of The Mayo Clinic Discusses Updates In Myeloid Disorders: How To Calculate The Blast In Myelodysplastic Syndrome, New Treatments, Safety, & Ongoing Trials.

Aref Al-Kali MD Of The Mayo Clinic Discusses How To Use Drugs In Patients With Myeloid Disorders: Focusing On Azacitidine & Decitabine, When To Dose Reduce A Drug & When To Give Less Days Of The Drug.

Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses Some That Image Well Do Not Respond: BRCA2 Is Associated With A Better Outcome While p53 Alterations May Have A Worse Prognosis. BACKROUND: Testosterone suppression (TS) is the backbone of treatment for mHSPC. OS is improved by the addition of early docetaxel (DOC) or abiraterone to TS. ENZAMET assessed the effects of enzalutamide (ENZA), a potent androgen receptor (AR) inhibitor, versus a nonsteroidal anti-androgen (NSAA: bicalutamide, nilutamide, or flutamide) in addition to SOC (TS with or without DOC) in mHSPC. METHODS: Men with mHSPC were randomly assigned 1:1 to…

Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses If They Are Imaging Negative, How Are They Responding: No Imaging Modality Is Perfect, 80% Use Plain Imaging Which Is Not As Sensitive As What Were Doing Now. BACKROUND: Patients (pts) with advanced urothelial cancer (UC) who progress after checkpoint inhibitor (CPI) therapy (following failure of or ineligibility for platinum-based chemotherapy) have limited options. Trop-2 is an epithelial cell surface antigen overexpressed in UC (Avellini. Oncotarget 2017). Sacituzumab govitecan (SG) is an antibody-drug conjugate that targets Trop-2 and delivers the active metabolite SN38 of the topoisomerase I inhibitor irinotecan…

Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer.BACKROUND: Patients (pts) with advanced urothelial cancer (UC) who progress after checkpoint inhibitor (CPI) therapy (following failure of or ineligibility for platinum-based chemotherapy) have limited options. Trop-2 is an epithelial cell surface antigen overexpressed in UC (Avellini. Oncotarget 2017). Sacituzumab govitecan (SG) is an antibody-drug conjugate that targets Trop-2 and delivers the active metabolite SN38 of the topoisomerase I inhibitor irinotecan to tumor cells (Starodub. Clin Cancer Res 2015). In a phase 1/2…

Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses Targeting PSMA: Patients That Have At Least One Bright Image Tend To Have A Better Chance At Responding. BACKROUND: Prostate surface membrane antigen (PSMA) is usually overexpressed in PC and is enriched in castration-resistant tumors. PSMA-TRT is of increasing interest to the field. Many in the field of theranostics have assumed that PSMA uptake on imaging is a pre-requisite for response. We have conducted a number of trials which have incorporated PSMA imaging, but have not selected patients for treatment based upon imaging results and performed an analysis examining…

Mark Fleming MD Of US Oncology Research Discusses Treatment Sequencing For Castrate Resistant M0 Disease: Looking At 3 Drugs Enzalutamide, Apalutamide, & Darolutamide, The Options Are The Challenge.

Mark Fleming MD Of US Oncology Research Discusses TITAN Trial: Many Options Including Chemo, Abiraterone, Enzalutamide, & Apalutamide All Showing A Benefit.